Background/Aims Polymorphism at the IL28B gene may modify the course of hepatitis C virus (HCV) chronic infection. Our aim was to study the influence of IL28B rs12979860 gene polymorphism on the biochemistry and pathology of HCV-induced disease in the clinical course from mild chronic hepatitis C to hepatocellular carcinoma. Methods We have determined the rs12979860 single nucleotide polymorphism (SNP) upstream IL28B gene in two groups of patients with HCV-induced chronic liver disease: 1) 268 patients (159 men) with biopsy-proven chronic hepatitis C, to analyse its relation with biochemical, virological and histological features; and 2) 134 patients (97 men) with HCV-related hepatocellular carcinoma. The distribution of the analysed SNP in hepatocellular carcinoma patients was compared with that found in untreated chronic hepatitis C patients. All patients were white and most were Spaniards. Results In multivariate analysis ALT values were higher (P = 0.001) and GGT values were lower (P<0.001) in chronic hepatitis C patients homozygotes for the major rs12979860C allele as compared with carriers of the mutated rs12979860T allele. Steatosis was more frequent (Odds ratio = 1.764, 95% C.I. 1.053–2.955) and severe (P = 0.026) in carriers of the rs12979860T allele. No relation was found between the analysed SNP and METAVIR scores for necroinflammation and fibrosis, and there were no differences in the distribution of the analysed SNP between hepatocellular carcinoma and untreated chronic hepatitis C patients. Conclusion The IL28B rs12979860 polymorphism correlates with the biochemical activity and the presence and severity of liver steatosis in chronic hepatitis C.
References
[1]
Seeff LB (2002) Natural history of chronic hepatitis C. Hepatology 36: S35–S46. [PMID: 12407575].
[2]
Chen SL, Morgan TR (2006) The natural history of hepatitis C virus (HCV) infection. Int J Med Sci 3: 47–52. [PMID: 16614742].
[3]
Seeff LB (2009) The history of the “natural history” of hepatitis C (1968–2009) Liver Int 29 Suppl 1: 89–99. [PMID: 19207971].
[4]
Bissell DM (1999) Sex and hepatic fibrosis. Hepatology 29: 988–989. [PMID: 10551508].
[5]
Williams MJ, Lang-Lenton M, Trent HCV study group (2011) Progression of initially mild hepatic fibrosis in patients with chronic hepatitis C infection. J Viral Hepat 18: 17–22. [PMID: 20088889].
[6]
Martínez C, García-Martín E, Ladero JM, Herráez O, Ortega L, et al. (2007) GSTT1 and GSTM1 null genotypes may facilitate hepatitis C virus infection becoming chronic. J Infect Dis 195: 1320–1323. [PMID: 17397002].
[7]
Minton EJ, Smillie D, Neil KR, Irving WL, Underwood JC, et al. (1998) Association between MHC class II alleles and clearance of circulating hepatitis C virus. J Infect Dis 178: 39–44.[PMID: 9652421].
[8]
Singh R, Kaul R, Kaul A, Khan K (2007) A comparative review of HLA associations with hepatitis B and C viral infections across global populations. World J Gastroenterol 13: 1770–1787. [PMID: 17465466].
[9]
Wang H, Mengsteab S, Tag CG, Gao CF, Hellerbrand C, et al. (2005) Transforming growth factor-beta1 gene polymorphisms are associated with progression of liver fibrosis in Caucasians with chronic hepatitis C infection. World J Gastroenterol 11: 1929–1936. [PMID: 15800982].
[10]
Kunzler S, Baumann M, Schirmacher F, Dries V, Bayer E, et al. (2001) Prediction of progressive liver fibrosis in hepatitis C infection by serum and tissue levels of transforming growth factor-β. J Virol 8: 430–437. [PMID: 11703574].
[11]
Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, et al. (2009) Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 461: 399–401. [PMID: 19684573].
[12]
Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, et al. (2009) IL28B is associated with response to chronic hepatitis C interferon-α and ribavirin therapy. Nature Genetics 41: 1100–1104. [PMID: 19749758].
[13]
Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, et al. (2009) Genome-wide association of IL28B with response to pegylated interferon-α and ribavirin therapy for chronic hepatitis C. Nature Genetics 41: 1105–1109. [PMID: 19749757].
[14]
Balagopal A, Thomas DL, Thio CL (2010) IL28B and the control of hepatitis C virus infection. Gastroenterology 139: 1865–1876. [PMID: 20950615].
[15]
Afdhal NH, McHutchison JG, Zeuzem S, Mangia A, Pawlotsky JM, et al. (2010) Hepatitis C pharmacogenetics: State of the art in 2010. Hepatology 53: 336–345. [PMID: 21254181].
[16]
Honda M, Sakai A, Yamashita T, Nakamoto Y, Mizukoshi E, et al. (2010) Hokuriku Liver Study Group. Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C. Gastroenterology 139: 499–509. [PMID: 20434452].
[17]
Urban TJ, Thompson AJ, Bradrick SS, Fellay J, Schuppan D, et al. (2010) IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C. Hepatology 52: 1888–1896. [PMID: 20931559].
[18]
Ahlenstiel G, Booth DR, George J (2010) IL28B in hepatitis C virus infection: translating pharmacogenomics into clinical practice. J Gastroenterol 45: 903–910. [PMID: 20635099].
[19]
Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, et al. (2009) Genetic variation on IL28B and spontaneous clearance of hepatitis C virus. Nature 461: 798–801. [PMID: 19759533].
[20]
Montes-Cano MA, García-Lozano JR, Abad-Molina C, Romero-Gómez M, Barroso N, et al. (2010) Interleukin-28B genetic variants and hepatitis virus infection by different viral genotypes. Hepatology 52: 33–37. [PMID: 20578254].
[21]
Tillmann HL, Thompson AJ, Patel K, Wiese M, Tenckhoff H, et al. (2010) German Anti-D Study Group. A polymorphism near IL28B is associated with spontaneous clearance of acute hepatitis C virus and jaundice. Gastroenterology 189: 1586–1592. [PMID: 20637200].
[22]
McCarthy JJ, Li JH, Thompson A, Suchindran S, Lao XQ, et al. (2010) Replicated association between IL28B gene variant and a sustained response to pegylated interferon and ribavirin. Gastroenterology; 138: 2307–2314. [PMID: 20176026].
[23]
Thompson AJ, Muir AJ, Sulkowski MS, Ge D, Fellay J, et al. (2010) Interleukin-28B polymorphism improves viral kinetics and is the strongest pre-treatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology 139: 120–129. [PMID: 20399780].
[24]
St？ttermayer AF, Stauber R, Hofer H, Rutter K, Beinhardt S, et al. (2011) Impact of IL28B genotype on the early and sustained virologic response in treatment-na？ve patients with chronic hepatitis C. Clin Gastroenterol Hepatol 9: 344–350. [PMID: 20728570].
[25]
Hayes CN, Kobayashi M, Akuta N, Suzuki F, Kumada H, et al. (2011) HCV substitutions and IL28B polymorphisms on outcome of peg-interferon plus ribavirin combination therapy. GUT 60: 261–267. [PMID: 21068134].
[26]
Rauch A, Kutalik Z, Descombes P, Cai T, Di Iulio J, et al. (2010) Swiss Hepatitis C Cohort Study; Swiss HIV Cohort Study. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology 138: 1338–1345. [PMID: 20060832].
[27]
Kurosaki M, Tanaka Y, Nishida N, Sakamoto N, Enomoto N, et al. (2011) Pre-treatment prediction of response to pegylated-interferon plus ribavirin for chronic hepatitis C using genetic polymorphism in IL28B and viral factors. J Hepatol 54: 439–448. [PMID: 21129805].
[28]
Ladero JM, García-Martín E, Fernández C, Carballo M, Devesa MJ, et al. (2012) Predicting response to therapy in chronic hepatitis C: An approach combining interleukin-28B gene polymorphisms and clinical data. J Gastroenterol Hepatol 27: 279–285. [PMID: 21722179].
[29]
Abe H, Ochi H, Maekawa T, Hayes CN, Tsuge M, et al. (2010) Common variation of IL28 affects gamma-GTP levels and inflammation of the liver in chronically infected hepatitis C virus patients. J Hepatol 53: 439–443. [PMID: 21145800].
[30]
Lencioni R (2011) Evolving strategies in the diagnosis of hepatocellular carcinoma. J Hepatol 54: 184–186. [PMID: 20950887].
[31]
Heid CA, Stevens J, Livak KJ, Williams PM (1996) Real time quantitative PCR. Genome Res 6: 989–994. [PMID: 8908518].
[32]
Witth？ft TH, M？ller B, Wiedmann KH, Mauss S, Link R, et al. (2007) Safety, tolerability and efficacy of peginterferon alpha-2a and ribavirin in chronic hepatitis C in clinical practice: The German Open Safety Trial. J Viral Hepat 14: 788–796. [PMID: 17927615].
[33]
The French METAVIR Cooperative Study Group (1994) Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. Hepatology 20: 15–20. [PMID: 8020885].
[34]
Brunt E, Janney C, Di Bisceglie A, Neuschwander-Tetri B, Bacon B (1999) Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 94: 2467–2474.[PMID: 10484010].
[35]
Thompson AJ, Clark PJ, Zhu M, Zhu Q, Ge D, et al. (2010) Genome wide-association study identifies IL28B polymorphism to be associated with baseline ALT and hepatic necro-inflammatory activity in chronic hepatitis C patients enrolled in the IDEAL study. Hepatology 52 (Suppl). pp. 1220A–1221A.
[36]
Bochud P-Y, Bibert S, Kutalik Z, Patin E, Guergnon J, et al. (2012) IL28B alleles associated with poor hepatitis C virus (HCV) clearance protect against inflammation and fibrosis in patients infected with non-1 HCV genotypes. Hepatology 55: 384–94. [PMID: 22180014].
[37]
Di Marco V, Bronte F, Calvaruso V, Capra M, Borsellino Z, et al. (2011) IL28B polymorphisms influence stage of liver fibrosis and spontaneous or interferon-induced viral clearance in thamassemia patients with hepatitis C virus infection. Haematologica [Epub ahead of print] [PMID: 22180419].
[38]
Falleti E, Bitetto D, Fabris C, Cussigh A, Fornasiere E, et al. (2011) Role of interleukin 28B rs12979860 C/T polymorphism on the histological outcome of chronic hepatitis C: relationship with gender and viral genotype. J Clin Immunol 31: 891–899. [PMID: 21747799].
[39]
Thompson AJ, Clark PJ, Fellay J, Muir AJ, Tillmann HL, et al. (2010) IL28B genotype is not associated with advanced hepatic fibrosis in chronic hepatitis C patients enrolled in the IDEAL study. Hepatology 52 (Suppl). pp. 437A–438A.
[40]
Fabris C, Falleti E, Cussigh A, Bitetto D, Fontanini E, et al. (2011) IL-28B re12979060 C/T allele distribution in patients with liver cirrhosis: Role in the course of chronic viral hepatitis and the development of HCC. J Hepatol 54: 716–722. [PMID: 21146242].
[41]
Li JH, Lao XQ, Tillmann HL, Rowell J, Patel K, et al. (2010) Interferon-lambda genotype and low serum low-density lipoprotein cholesterol levels in patients with chronic hepatitis C infection. Hepatology 51: 1904–1911. [PMID: 20235331].
[42]
Tillmann HL, Patel K, Muir AJ, Guy CD, Li JH, et al. (2011) Beneficial IL28B genotype associated with lower frequency of hepatic steatosis in patients with chronic hepatitis C. J Hepatol 55: 1195–2000. [PMID: 21703198].
[43]
Ohnishi M, Tsuge M, Kohno T, Zhang Y, Abe H, et al. (2012) IL28B polymorphism is associated with fatty change in the liver of chronic hepatitis C patients. J Gastroenterol [Epub ahead of print].[PMID: 22350701].
[44]
Miura M, Maekawa S, Kadokura M, Sueki R, Komase K, et al. (2011) Analysis of viral amino acids sequences and the IL28B SNP influencing the development of hepatocellular carcinoma in chronic hepatitis C. Hepatol Int [Epub ahead of print]. [PMID: 22022823].
[45]
Joshita S, Umemura T, Katsuyama Y, Ichikawa Y, Kimura T, et al. (2011) Association of IL28B gene polymorphism with development of hepatocellular carcinoma in Japanese patients with chronic hepatitis C virus infection. Hum Immunol 73; 298–300. [PMID 22245236].
[46]
Asahina Y, Tanaka K, Suzuki Y, Tamaki N, Hoshioka T, et al. (2011) Association between IL28B gene variation and development of hepatocellular carcinoma after interferon therapy in patients with chronic hepatitis C. J Hepatol 54 (Suppl 1): S37.
[47]
Trapero-Marugán M, Mendoza J, Chaparro M, González-Moreno L, Moreno-Monteagudo JA, et al. (2011) Long-term outcome of chronic hepatitis C patients with sustained virological response to interferon plus ribavirin. World J Gastroenterol 17: 493–498. [PMID: 21274379].
[48]
Maruoca D, Imazeki F, Arai M, Kanda T, Fujiwara K, et al. (2012) Long-term cohort study of chronic hepatitis C according to interferon efficacy. J Gastroentrol Hepatol 27: 291–299. [PMID: 21793911].
[49]
Eurich D, Boas-Knoop S, Bahra M, Neuhaus R, Somasundaram R, et al. (2012) Role of IL28B polymorphism in the development of hepatitis C virus-induced hepatocelular carcinoma, graft fibrosis, and posttransplant activiral therapy. Transplantation 93: 644–649 [PMID: 22411462].
[50]
Ren S, Lu J, Du X, Huang Y, Ma L, et al. (2012) Genetic variation in IL28B is associated with the development of hepatitis B-related hepatocellular carcinoma. Cancer Immunol Immunother [Epub ahead of print]. [PMID: 22310928].
[51]
Cuenca F, Fernández C, Devesa MJ, López-Alonso G, Mayol J, et al. (2010) Predictive baseline criteria of primary therapeutic failure in chronic hepatitis C genotype 1. Rev Esp Enferm Dig 102: 234–238. [PMID 20486745].
